Sign up
Log in
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
Share
Listen to the news

These large-cap stocks were the worst performers in the last week. Are they in your portfolio?

  1. argenx SE (NASDAQ:ARGX) shares tumbled 15.40% after the company reported first-quarter results.
  2. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares dipped 15.20% after it reported lower-than-expected first-quarter 2025 earnings, and analysts revised the price forecasts.
  3. Summit Therapeutics Inc. (NASDAQ:SMMT) stock fell 14.12%.
  4. MakeMyTrip Limited (NASDAQ:MMYT) shares dived 12.96%.
  5. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares fell 12.85%. The U.S. Food and Drug Administration (FDA) announced its intent to expand the use of unannounced inspections at foreign manufacturing facilities that produce foods, essential medicines, and other medical products intended for American consumers and patients.
  6. Rocket Companies, Inc. (NYSE:RKT) shares dived 11.97% after reporting first-quarter results, but issuing a weaker-than-expected Q2 sales outlook.
  7. BioNTech SE (NASDAQ:BNTX) stock was down 11.60% after the company reported quarterly results. Analysts revised the price forecast on the stock.
  8. Affirm Holdings, Inc. (NASDAQ:AFRM) stock declined 11.33% after the company reported third-quarter results and analysts revised the price forecast.
  9. FNF Group of Fidelity National Financial, Inc. (NYSE:FNF) stock declined 10.98% after the company reported first-quarter results.
  10. Eli Lilly and Company (NYSE:LLY) stock fell 10.81% last week in reaction to an executive order from the Trump administration to boost domestic drug manufacturing.
  11. Aurora Innovation, Inc. (NASDAQ:AUR) stock declined 10.57% after the company reported its first-quarter financial results. Analysts revised the stock’s price forecast.
  12. DoorDash, Inc. (NASDAQ:DASH) shares decreased 10.52% after announcing downbeat first-quarter sales, and analysts revised the price forecast.

Photo by Jonathan Weiss via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.